# A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

> **NCT04523272** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 528 (actual)

## Conditions studied

- Advanced Renal Cancer

## Interventions

- **DRUG:** TQB2450
- **DRUG:** Anlotinib
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT04523272
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-25
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 528 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523272, "A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04523272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*